Test of Vascular Function May Predict Solid-Tumor Cancer Risk

Reactive hyperemia peripheral arterial tonometry index ≤2.0 predicted incidence of solid-tumor cancer

THURSDAY, Nov. 7, 2019 (HealthDay News) -- Microvascular endothelial dysfunction is associated with an increased risk for solid-tumor cancer, according to a study published online Oct. 31 in the European Journal of Preventive Cardiology.

Takumi Toya, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the predictive value of microvascular endothelial dysfunction for future risk for solid-tumor cancer in 488 patients who underwent microvascular endothelial function assessment using reactive hyperemia peripheral arterial tonometry.

The researchers found that 9.5 and 3.7 percent of patients with a baseline reactive hyperemia peripheral arterial tonometry index ≤2.0 (defined as microvascular endothelial dysfunction) and >2.0, respectively, were diagnosed with incident solid-tumor cancer during follow-up. Compared with patients with a reactive hyperemia peripheral arterial tonometry index >2.0, those with a reactive hyperemia arterial tonometry index ≤2.0 had lower solid-tumor cancer-free survival during a median follow-up of six years. The incidence of solid-tumor cancer was predicted by reactive hyperemia peripheral arterial tonometry index ≤2.0, with a hazard ratio of 2.52 after adjustment for age, sex, and coronary artery disease. Hazard ratios were 2.83 after adjusting for diabetes mellitus, hypertension, smoking status, and body mass index >30 kg/m²; 2.79 after adjusting for fasting plasma glucose, systolic blood pressure, smoking status (current or former), and body mass index; and 2.43 after adjusting for the Framingham risk score.

"This abnormal vasoreactivity should alert clinicians not only to the risk of cardiovascular disease but to malignancy, as well," a coauthor said in a statement. "This risk prediction appears to precede the development of disease by more than five years."

One author disclosed financial ties to Itamar Medical.

Abstract/Full Text

Last Updated: